Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Abbreviated New Drug Application (ANDA): 202024
Company: AMNEAL PHARMS

Products on ANDA 202024

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
GABAPENTIN	GABAPENTIN	250MG/5ML	SOLUTION;ORAL	Prescription	AA	No	No

Approval Date(s) and History, Letters, Labels, Reviews for ANDA 202024

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
03/23/2012	ORIG-1	Approval	Not Applicable			Label is not available on this site.

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
11/08/2014	SUPPL-2	Labeling-Package Insert		Label is not available on this site.
11/08/2014	SUPPL-1	Labeling-Package Insert		Label is not available on this site.

Therapeutic Equivalents for ANDA 202024

GABAPENTIN

SOLUTION;ORAL; 250MG/5ML
TE Code = AA

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
GABAPENTIN	GABAPENTIN	250MG/5ML	SOLUTION;ORAL	Prescription	No	AA	076403	ACELLA PHARMS LLC
GABAPENTIN	GABAPENTIN	250MG/5ML	SOLUTION;ORAL	Prescription	No	AA	202024	AMNEAL PHARMS
GABAPENTIN	GABAPENTIN	250MG/5ML	SOLUTION;ORAL	Prescription	No	AA	217682	ANNORA PHARMA
GABAPENTIN	GABAPENTIN	250MG/5ML	SOLUTION;ORAL	Prescription	No	AA	091286	BELCHER
GABAPENTIN	GABAPENTIN	250MG/5ML	SOLUTION;ORAL	Prescription	No	AA	078974	MISSION PHARMACAL
GABAPENTIN	GABAPENTIN	250MG/5ML	SOLUTION;ORAL	Prescription	No	AA	216492	RUBICON
GABAPENTIN	GABAPENTIN	250MG/5ML	SOLUTION;ORAL	Prescription	No	AA	076672	TARO
NEURONTIN	GABAPENTIN	250MG/5ML	SOLUTION;ORAL	Prescription	Yes	AA	021129	VIATRIS